India’s Supreme Court denied the request of Novartis for patent protection of its Gleevec cancer treatment, allowing the nation’s generic-drug makers to continue to sell copies of the drug at a lower price.

The court upheld regulatory rulings dating to 2006 that the drug was not sufficiently innovative to merit a patent. The decision was watched by non-profit groups seeking to expand access to medicines and drug makers concerned about India’s position on intellectual property.

Embedded Link

Novartis Cancer-Drug Patent Denied by India Supreme Court
India’s Supreme Court denied Novartis AG’s request for patent protection for its Gleevec cancer treatment, allowing the nation’s generic-drug makers to continue to sell copies of the drug at a lower p…

Google+: View post on Google+

Tags:

Comments are closed.